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Abstract: Ghrelin, an orexigenic peptide synthesized by endocrine cells of the gastric mucosa, is released in the blood-
stream in response to a negative energetic status. Since discovery, the hypothalamus was identified as the main source of 
ghrelin in the CNS, and effects of the peptide have been mainly observed in this area of the brain. In recent years, an in-
creasing number of studies have reported ghrelin synthesis and effects in specific populations of neurons also outside the 
hypothalamus. Thus, ghrelin activity has been described in midbrain, hindbrain, hippocampus, and spinal cord. The spec-
trum of functions and biological effects produced by the peptide on central neurons is remarkably wide and complex. It 
ranges from modulation of membrane excitability, to control of neurotransmitter release, neuronal gene expression, and 
neuronal survival and proliferation. There is not at present a general consensus concerning the source of ghrelin acting on 
central neurons. Whereas it is widely accepted that the hypothalamus represents the most important endogenous source of 
the hormone in CNS, the existence of extra-hypothalamic ghrelin-synthesizing neurons is still controversial. In addition, 
circulating ghrelin can theoretically be another natural ligand for central ghrelin receptors. This paper gives an overview 
on the distribution of ghrelin and its receptor across the CNS and critically analyses the data available so far as regarding 
the effects of ghrelin on central neurotransmission.  
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INTRODUCTION 
  In the last years, ghrelin, a peptide ligand of the growth 
hormone secretagogue receptor (GHS-R), has gained in-
creasing attention as a brain-gut hormone [82, 83, 86]. Ghre-
lin displays several biological effects such as regulation of 
feeding, gastric secretion and motility, fat mass deposition, 
and cell proliferation [4, 37, 42, 91, 160], but has gained 
increasing attention mainly for its effects on feeding behav-
ior and metabolism [48, 54, 64, 121]. Whereas, it is widely 
accepted that the control of food intake occurs through acti-
vation of specific hypothalamic nuclei and the promotion of 
neuropeptide Y (NPY) and Agouti related protein (AgRP) 
expression [4, 5, 103, 142, 145, 148, 157], the distribution of 
GHS-R in central nervous system (CNS), and the modulation 
of neurotransmission in extra-hypothalamic areas suggest 
broader effects than originally predicted.  
  We will review below the most relevant data in the litera-
ture as regarding to the distribution and function of ghrelin 
and its receptor in central neurons linked to a neurotransmit-
ter role of the peptide. 
HISTORICAL NOTES, BIOCHEMISTRY AND DIS-
TRIBUTION OF GHRELIN IN CNS 
  Ghrelin is a 28-amino acid motilin-related peptide [4], 
originally purified from the rat stomach [81]. The peptide is 
characterized by the presence of an n-octanoylation on the 
hydroxy group of serine in position 3. This acylation is a 
post-transcriptional modification that is essential for binding  
*Address correspondence to this author at Dipartimento di Morfofisiologia 
Veterinaria, Università di Torino, Via Leonardo da Vinci 44, 10095 Grugli-
asco, Italy, EU; Tel: +390116709118; fax: +390112369118;  
E-mail: adalberto.merighi@unito.it 
to GHS-R [81, 145] to a point that ghrelin was originally 
supposed to be biologically active only in acylated form 
[81]. However, about 80-90% of circulating ghrelin is not 
acylated (des-acyl-ghrelin), and it still remains unclear 
whether or not des-acyl-ghrelin represents a precursor or a 
degradation product of the acylated peptide [65, 83]. Moreo-
ver, des-acyl-ghrelin does not replace radio labeled ghrelin at 
pituitary and hypothalamic binding sites, nor it seems capa-
ble of inducing growth hormone (GH) release. Therefore its 
biological role, if any, remains puzzling, and the possibility 
that des-acyl-grelin is a biologically active molecule acting 
through a specific, but yet uncharacterized receptor still re-
mains a matter of debate. In support of this hypothesis, sev-
eral  in vitro studies have demonstrated that radio labeled 
ghrelin and des-acyl-ghrelin bind to the membranes of PC-3 
prostate tumor cells, H9C2 cardiomyocytes and isolated adi-
pocytes, none of which expressed the GHS-R [6, 24, 101]. In 
addition, ghrelin and des-acyl-ghrelin, at least in some cases, 
exhibit similar GHS-R independent biological activities, 
such as the inhibition of cell proliferation of breast carci-
noma cell lines [23], the ionotropic effect on guinea pig pap-
illary muscle [9], the promotion of bone marrow adipogene-
sis [138], the control of glucose output by primary hepato-
cytes [47]. 
  Circulating ghrelin is mainly produced by X/A-like cells 
of the oxyntic stomach mucosa [3, 34, 41, 120, 154]. How-
ever, expression of the peptide has also been demonstrated in 
many other organs such as testis [136], ovary [19], placenta 
[55], kidney [100], pituitary [85], small intestine [34], pan-
creas [147], lymphocytes [61] and brain [33, 40, 90, 140]. 
  In CNS, the main site of ghrelin synthesis (albeit at much 
lower levels than the stomach) is the hypothalamus. Expres-
sion of ghrelin in brain was initially established in the semi-38    Current Neuropharmacology, 2009, Vol. 7, No. 1 Ferrini et al. 
nal paper by Kojima and co-workers [81]. Later, by using a 
combination of RIA and HPLC, Sato and co-workers clearly 
identified hypothalamic ghrelin [123]. By immunocyto-
chemical techniques and colchicine pre-treatments, ghrelin 
expression was demonstrated in the internuclear space be-
tween the lateral hypothalamus, the arcuate nucleus (ARH), 
the ventromedial nucleus (VMN), the dorsomedial nucleus 
(DMN), the paraventricular nucleus (PVN) and the ependy-
mal layer of the third ventricle [33, 66]. In these areas, ghre-
lin was localized in axon terminals innervating the ARH, 
VMN, PVN, DMN and the lateral hypothalamus. These ax-
ons made synapses with neurons expressing NPY/AgRP and 
pro-opiomelanocortin (POMC) [33]. However, according to 
other immunocytochemical studies, ghrelin is also synthe-
sized by ARH neurons and these ghrelin-producing neurons 
display synaptic interactions with POMC, NPY and other 
ghrelin-containing nerve cells [57, 58, 63, 90]. These find-
ings were confirmed by RT-PCR experiments [98] and, very 
recently, by the use of transgenic mice where the transcrip-
tion regulatory regions of the ghrelin gene have been engi-
neered to drive the expression of enhanced green fluorescent 
protein (EGFP) [74]. Finally, expression of the hormone in 
hypothalamus was also detected in human samples [95].  
  Outside the hypothalamus, ghrelin-immunopositive stain-
ing was observed in pyramidal neurons of layer V in the sen-
sorimotor area and in the cingulate gyrus of the cerebral cor-
tex, and the ghrelin mRNA was found in the sensorimotor 
cortex and in the dorsal vagal complex (DVC) of the medulla 
oblongata [66]. 
  Localization in spinal cord and dorsal root ganglion 
(DRG) neurons remains to be ascertained with certainty, 
albeit after tyramide intensification we observed a limited 
number of positive medium-to-large DRG neurons and occa-
sional cell bodies in laminae IV-IX of the spinal gray matter 
(unpublished data). 
BIOCHEMISTRY, FUNCTIONAL PROPERTIES AND 
DISTRIBUTION OF GHRELIN RECEPTOR(S) IN 
CNS
  The GHS-R is a seven transmembrane-spanning domain 
G-protein coupled receptor that activates phospholipase C 
(PLC) via G11/Gq11-protein [29, 67, 94, 113]. Consequently, 
PLC increases the intracellular Ca
2+ levels, through inositol-
3-phopshate (IP3)- and protein kinase C (PKC)-dependent 
pathways [2, 92]. Nifepidine and -agatoxin IIIA, but not 
conotoxin, inhibit the GHS-dependent Ca
2+ increase, consis-
tently with an activation of L-type calcium channels. This 
depolarizing effect is further strengthened by the inhibition 
of K
+ channels, which probably involves the activation tran-
sient outward and delayed rectifier potassium channels [60]. 
  In 1996, Howard and coll. [67] sequenced two cDNA 
clones encoding for two different GHS-R isoforms that were 
named type 1a and type 1b. Type 1a encodes for the full-
length biologically active receptor. Conversely, type 1b en-
codes for a truncated isoform, lacking the transmembrane 
domains 6 and 7 of the type 1a, that is therefore thought to 
represent a non-functional receptor form [94]. In keeping 
with this assumption, binding affinity studies have shown 
that GHS secretagogues only bind GHS-R type 1a. Nonethe-
less, in HEK293 cells co-expressing full-length and trun-
cated receptor isoforms it has been recently observed that 
GHS-R type 1b may play a regulatory/inhibitory role on type 
1a receptor activity [26].  
  The distribution of GHS-R type 1a was investigated both 
in human and animal tissues using different techniques such 
as Western blotting, immunohistochemistry, in situ hybridi-
zation and radioimmunoassay [11, 49, 56, 97, 109, 126, 137, 
164]. In these studies, GHS-receptors were localized in non-
nervous organs/tissues (including adipose tissue, myocar-
dium, adrenals, gonads, lung, liver, arteries, stomach, pan-
creas, thyroid, and kidney) as well as in CNS, with different 
levels of expression.  
  In CNS, GHS-R type 1a is highly expressed in the ARH 
and VMN of hypothalamus [11, 56, 66, 67, 97]. Co-
expression of GHS-R with GH-releasing hormone, NPY, 
POMC, somatostatin, and tyrosine hydroxylase (TH) was 
also investigated in these areas [126, 137, 151]. Outside the 
hypothalamus, a positive receptor signal was observed in the 
cerebral cortex, dentate gyrus, CA2 and CA3 regions of the 
hippocampus, parafascicular thalamic region, substantia ni-
gra, ventral tegmental area, raphe nuclei, nodose ganglion, 
and DVC [16, 17, 18, 40, 56, 66, 164]. By RT-PCR, Western 
blotting and immunohistochemistry we demonstrated the 
presence of GHS-R type 1a in mouse spinal cord [146]. After 
RT-PCR in situ, the mRNA was observed in neuronal cell 
bodies scattered across the base and neck of the dorsal horn. 
Following immunohistochemical labeling, positive neurons 
of corresponding sizes were observed in the same locations. 
Parallel patch clamp experiments demonstrated that these 
receptors were functional in vitro.
GHRELIN AND FEEDING CIRCUITRY 
  According to a recent definition, a neurotransmitter is a 
molecule, released by neurons or glia that physiologically 
influences the electrochemical state of adjacent cells [129]. 
In this respect, the first evidence that ghrelin may act as neu-
rotransmitter in CNS was provided by studies on the hypo-
thalamic neurons involved in the control of feeding [72]. The 
physiological significance of the biological functions of 
ghrelin on nutritional homeostasis and metabolism has been 
authoritatively reviewed [32, 72, 108].  
  Besides to these widely acknowledged functions, initial 
electrophysiological studies in hypothalamus strongly sug-
gested that ghrelin also modulates neuronal excitability and 
synaptic transmission by acting on GHS-R type 1a [33, 117, 
140, 144]. The main site of action of the hormone was found 
in ARH (Fig. 1A), where ghrelin-positive terminals innervate 
a population of GHS-R type 1a expressing neurons [33, 125, 
164]. Within ARH, ghrelin was shown to increase the firing 
rate of a population of neurons that were inhibited by the 
anorexigenic peptide leptin [117, 140]. The effect was partly 
blocked by the GHS-R type 1a antagonist (D-Lys3)-GHRP-6 
[139]. The mechanism and the circuitry involved were eluci-
dated in the interesting study of Cowley and coll. [33]. These 
authors used an acute slice preparation from hypothalamus 
obtained from two lines of transgenic mice in which NPY- or 
POMC-expressing neurons were genetically engineered to 
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Fig. 1. Ghrelin modulation of inhibitory neurotransmission in central neurons. A. In the hypothalamic ARH, GHS-Rs are expressed on 
axon terminals of NPY/AgRP-expressing inhibitory neurons. GHS-R activation at this level is supposed to induce the release of peptides such 
as NPY (thick arrows), more efficiently than aminoacids, such as GABA (thin arrow). NPY, in turn, inhibits anorexygenic POMC neurons by 
acting on postsynaptic Y1 receptors and disinhibits orexygenic CRH neurons by acting on pre-synaptic Y1-Y5 receptors, therefore reducing 
GABA release. The main source of ghrelin in this area of the brain is likely to be the circulating hormone that is capable to cross the BBB. 
However, a local source of ghrelin cannot be excluded, given that ghrelin-expressing neurons (squares) have also been described in ARH. B.
In the spinal cord deep dorsal horn (laminae IV-V), GHS-Rs are mainly expressed at the somato-dendritic domain of local inhibitory interneu-
rons. GHS-R activation leads to an action potential-dependent release of GABA and glycine onto putative projection neurons. The inhibition 
of these neurons reduces the outflow of sensory information (including pain) to higher centers (i.e. the thalamus). The source of spinal cord 
ghrelin is still under investigation, as it appears that ghrelin is locally expressed at very low levels (if any). Moreover, even though the exis-
tence of descending hypothalamic-spinal projections has been described, there are no data at present demonstrating a direct projection (dashed 
line) to the spinal cord from hypothalamic neurons synthesizing the peptide (square). Therefore also in spinal cord the most likely source of 
ghrelin remains the blood circulation.40    Current Neuropharmacology, 2009, Vol. 7, No. 1 Ferrini et al. 
lin was shown to directly increase the firing rate of NPY/ 
AgRP neurons and to indirectly inhibit POMC neurons by 
facilitating the pre-synaptic release of -amino butyric acid 
(GABA) and NPY. Furthermore, in PVN, the main projec-
tion site of ARH neurons, ghrelin reduced the inhibitory tone 
of corticotropin-releasing hormone (CRH) neurons through 
activation of pre-synaptic NPY receptor Y1 and Y5, thus 
disinhibiting an important orexigenic pathway mediated by 
these neurons. Taken together, the above observations dem-
onstrate that the effects of ghrelin on hypothalamic feeding 
circuitry are due to modulation of transmitter release from 
ARH neurons expressing NPY. Further confirmation was 
subsequently obtained after molecular genetic studies [28], 
where the effect of peripheral ghrelin on feeding behavior 
resulted to be reduced after NPY deletion (but not AgRP) 
and completely blocked in NPY/AgRP double knock-out 
animals. As observed by Cowley and Grove [32], the loss of 
ghrelin effect by simply switching off the NPY and AgRP 
genes excludes that the inhibitory effect of ghrelin onto 
POMC neurons is due to a direct facilitation of GABAergic 
transmission, but rather suggests that is largely mediated by 
peptide release.  
  Interestingly, by coupling patch-clamp recordings and 
single cell RT-PCR, van den Top and coll. [144] demon-
strated that ghrelin induces regular bursts of action potentials 
with underlying oscillation of membrane potentials in NPY/ 
AgRP-expressing ARH neurons. This ghrelin-induced pace-
maker activity is driven by low-threshold T-type Ca
2+ chan-
nels and the bursting frequency is modulated by transient 
outwardly rectifying K
+ currents. As demonstrated in the 
seminal paper of Poulain and Wakerley [114], burst activity 
is particularly effective in inducing peptide release from hy-
pothalamic neurons. Therefore ghrelin should more effi-
ciently modulate peptide release than amino acid release in 
ARH.  
  In a series of calcium imaging experiments on isolated 
ARH neurons, the activation of N-type Ca
2+ channels via
protein kinase A (PKA) was also proposed as a mechanism 
by which ghrelin may rise cytosolic Ca
2+ levels in NPY ex-
pressing neurons [78]. Within the same population of neu-
rons, ghrelin also elevates intracellular Ca
2+ concentration by 
actingviaphospholipase C and AMP-activated protein kinase 
[79, 80]. The increase of cytosolic Ca
2+, besides changing 
membrane excitability, is generally known to activate many 
intracellular pathways that regulate protein synthesis and 
metabolism. In keeping with this notion, several lines of evi-
dence suggest that ghrelin may regulate gene expression and 
de novo synthesis of other neurotransmitters [51, 103, 125]. 
In particular, intracerebroventricular (ICV) administration of 
orexigenic doses of ghrelin increases the mRNA level of 
AgRP and NPY in ARH neurons [103, 125], and a similar 
effect (even though conditional to the co-administration of 
corticosteroids) was observed in a hypothalamic organotypic 
culture model [51]. The stimulatory effects of ghrelin on 
NPY gene expression were abolished in the presence of cy-
cloheximide, that blocks protein translation [51]. Further-
more in several hypothalmic nuclei involved in feeding con-
trol (ARH, PVN, DVM, VMN and lateral hypothalamic nu-
clei), ICV injections of ghrelin were shown to increase ex-
pression of Fos, a marker of neuronal activation [87]. Inter-
estingly, the ghrelin-induced Fos expression was found in 
about 40% of NPY neurons in ARH [102, 148], but also in 
about 20% of orexin positive neurons in the lateral hypotha-
lamic nucleus [139] and in a population of oxytocin positive 
neurons in PVN [107], suggesting that complex interactions 
occur between hunger-related neurotransmitters. It has been 
very recently shown that also the cannabinoid system is di-
rectly involved in the orexygenic effects of ghrelin in the 
hypothalamus. Indeed, blockade of the cannabinoid receptor 
type 1 prevents the ghrelin-mediated increase of hypotha-
lamic AMP-activated protein kinase and inhibition of parvo-
cellular PVN neurons [84]. Finally, it has been shown that 
ghrelin induces a rapid rewiring of ARH feeding circuits 
with a decrease of excitatory synaptic inputs to POMC neu-
rons, while the inhibitory inputs were increased [111].  
  All together these studies suggest that the peptide acts as 
a neurotransmitter in the hypothalamus by modifying the 
output response of specific orexygenic neurons. Nonetheless, 
the biological effects of ghrelin in hypothalamus are not only 
restricted to modulation of neurotransmitter release at syn-
apses, but also encompass a series of modifications in gene 
expression, cell metabolism, and synaptic connectivity. In 
addition, ghrelin was shown to indirectly influence the hypo-
thalamic feeding circuitry by acting on the circumventricular 
organs. By using in vitro calcium imaging and patch clamp 
techniques, it was demonstrated that about 30% of the sub-
fornical organ (SFO) neurons respond to ghrelin with an 
increase of cytosolic calcium concentration and spiking 
[115]. The depolarizing effect is dose dependent and seems 
to be triggered by the activation of a voltage independent 
non-selective cation conductance. SFO neurons project to the 
hypothalamus and are placed in a strategic site for interaction 
with blood circulating peptides, since SFO displays a leaky 
blood-brain barrier (BBB) [31]. Therefore SFO neurons may 
represent an important relay station between humoral signals 
originating in the gastrointestinal tract and ghrelin-respon-
sive central neurons.  
  Broadly speaking, ghrelin-responsive hypothalamic neu-
rons respond with an increase of food intake in the presence 
of a negative energetic status [103]. Even though mainte-
nance of energy homeostasis is likely the most relevant ef-
fect in feeding behavior [13], ghrelin is also involved in the 
central regulation of other feeding-related aspects, such as 
the research of food for reward and the digestive function, by 
acting on midbrain and hindbrain areas, respectively [72, 
108].  
  The effect of ghrelin in midbrain has been recently de-
scribed in ventral tegmental area (VTA) and nucleus accum-
bens (Nacc) [1, 104]. Mesolimbic circuits located in VTA 
represent an important site for the generation of reward-
seeking behaviors, including those to obtain reward from 
food. The main neurotransmitter underlying these behaviors, 
but also involved in the reward for sexual experience and 
drug assumption, is dopamine (DA) [12, 130]. DA is synthe-
sized in VTA and substantia nigra and subsequently released 
onto Nacc and striatal neurons. Nanomolar concentrations of 
ghrelin were shown to increase the action potential fre-
quency of VTA dopaminergic neurons in vitro when slices 
were obtained from wild type animals, but not Ghsr
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[1]. In contrast with the experiments performed on ARH 
neurons [33, 111], ghrelin seems to act on VTA neurons in-
dependently from GABA-ergic neurotransmission, but rather 
inducing an increase and a significant plastic rearrangement 
of the excitatory input on DA neurons [1]. The results of 
these functional experiments were strengthened by histologi-
cal studies in which co-expression of GHS-R type 1a and 
DA receptors in VTA, as well as in other dopaminergic brain 
areas (i.e. the hippocampus and substantia nigra), was dem-
onstrated in a transgenic mouse model [71]. Interestingly, 
functional interactions between the two receptors amplify the 
DA signaling to VTA neurons. The ghrelin-induced potentia-
tion of DA neurotransmission stimulates the overflow of DA 
in the Nacc, and this mechanism has been proposed to under-
lie the increased locomotor activity which is observed in the 
context of the feeding seeking behavior [68, 69]. Very recent 
evidence has been provided to show that the DA-enhancing 
effect is likely the result of interplay between ghrelin and the 
cholinergic system, but the underlying mechanisms still re-
main at least partly elusive [70].  
  The main site of ghrelin action in the hindbrain is the 
DVC, an autonomic centre that includes the nucleus tractus 
solitarius (NTS), the dorsal motor nucleus of the vagus nerve 
(DMV) and the area postrema (AP) [43]. NTS and AP re-
ceive visceral afferent inputs that drive a number of auto-
nomic reflexes and relay visceral sensory information to 
other central stations that are involved in the control of en-
ergy balance [118, 124]. Moreover, DMV is a key centre for 
the parasympathetic control of the gastro-intestinal function 
and for central regulation of gastric secretion [119, 141]. In 
the DVC, ghrelin seems to affect both afferent and efferent 
signals. In keeping with this hypothesis, intravenously ad-
ministered ghrelin activates the vagal afferent pathways and 
transection of the vagus nerve reduces the hyperphagic ef-
fects of peripheral ghrelin [37]. ICV administrations and 
intraparenchimal injections of the hormone in the DVC were 
shown to increase food intake [43]. GHS-Rs are expressed in 
DVC neurons [164], and the hyperphagic effect was pro-
posed to be mediated by GHS-R expressing fibers running 
from NTS to the hypothalamus [38]. The signal activated by 
ghrelin reaches the ARH where it increases the release of 
noradrenaline [38]. On the other hand, ICV and intravenous 
injections of ghrelin induce an increase of Fos immunoreac-
tivity in neurons of NTS, DMV and AP and stimulate gastric 
acid secretion and pancreatic secretion via the efferent vagal 
pathways [36, 88]. The existence of a subset of ghrelin-
producing hypothalamic neurons that project to DVC has 
been revealed by immunohistochemistry, RT-PCR and tract 
tracing techniques [66]. Until recently there was a substantial 
lack of functional data in support to the idea that the hor-
mone acts as a neurotransmitter within DVC. However, in 
keeping with this idea, Wang and coll. [149] have shown that 
ghrelin modulates cell excitability in DVC by using in vivo
extracellular recordings.  
GHRELIN AND AROUSAL STATE 
  Several lines of evidence suggest that the effect of ghre-
lin in the hypothalamus is not only restricted to feeding be-
haviour and energy homeostasis, but also concerns the regu-
lation of sleep-wake states [131]. Again, somehow contradic-
tory results have been obtained by different authors. Sys-
temic administration of ghrelin was shown to promote sleep-
ing by increasing non-rapid eye movement sleep (NREMS) 
in mice [105], and slow wave sleep in humans [150]. Con-
versely, when administered intracerebroventricularly, ghrelin 
induced wakefulness and suppressed NREMS and rapid eye 
movements (REMS) in rats [132]. To identify the central site 
of ghrelin activity, Szentirmai and coll. [132] performed mi-
croinjections of the peptide in several hypothalamic areas 
implicated in sleeping and feed behavior. As predicted, in-
jections in the lateral hypothalamus, medial preoptic area and 
PVN induced wakefulness and hyperphagia. To explain the 
apparent contradiction between pro-sleep and pro-awake 
effects two different alternative pathways can be hypothe-
sized: the first one, controlled by circulating ghrelin, likely 
intervenes in growth hormone releasing hormone (GHRH) 
sleep-promoting mechanisms [105]; the second, controlled 
by central administered ghrelin, likely activates hypotha-
lamic wake-promoting mechanisms with the intervention of 
orexin and NPY [106, 134]. Unfortunately, ghrelin knock-
out mice were not very informative in clarifying the role of 
ghrelin in the arousal state, possibly as a consequence of the 
redundancy of the system [133]. In addition, very little is 
known concerning the molecular mechanisms and the under-
lying circuitry. Yi and coll. [158] have recently provided 
data in support to the notion that ghrelin modulates circadian 
activity by acting on the ARH-suprachiasmatic nucleus 
(SCN) axis. According to their experiments, peripheral ad-
ministrations of the ghrelin synthetic analogue GHRP-6 in-
hibit the light-induced Fos expression in rat SCN, following 
activation of NPY inhibitory neurons in the ARH. Moreover, 
by measuring locomotor activity in mice, the same authors 
showed that GHRP-6 shortens the light-induced phase shift 
[158]. Since SCN is an important biological clock which is 
sensitive to external photonic, as well as non-photonic fac-
tors, the mechanism described above may be at the basis of 
ghrelin modulation of the arousal state. As to our knowledge, 
no data are available at present on the neurotransmitters and 
receptors involved. Nonetheless, the monoaminergic and 
cholinergic systems are likely to be involved based on the 
results of similar studies focused on the orexin mechanisms 
in sleep/wake state [106].  
GHRELIN AND MEMORY 
  Hippocampus, amygdala and dorsal raphe nucleus (DRN) 
are the main brain areas involved in learning and memory 
mechanisms. Initial evidence suggesting that ghrelin may 
have a role in mnestic functions was provided by the early 
work of Carlini and coll. [20, 21]. First, by using a behav-
ioural test these authors showed that ICV injections of ghre-
lin increase memory retention [20]. To more precisely define 
the site of peptide action, the experiment was repeated after 
intraparenchimal injections of increasing concentrations of 
the hormone in hippocampus, amygdala and DRN [21]. A 
dose-dependent increase of memory retention was observed 
in each condition, with maximal effect in hippocampus. 
More recent data from the same laboratory suggest that the 
effects of ghrelin on memory could depend on the availabil-
ity of serotonin (5-HT), since a 5-HT uptake inhibitor (fluo-
xetine) decreases both short and long term memory retention 
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Diano and coll. [40], who showed that peripheral ghrelin 
injections rapidly rearrange synaptic organization with an 
increase in spine density in CA1 regions of hippocampus, 
similarly to hypothalamus [111] and midbrain [1]. Interest-
ingly, comparable results were also obtained after analysis of 
spine density in wild type and ghrelin knock-out animals, 
giving further support to involvement of endogenous ghrelin 
in CA1 spine formation. Furthermore, the same authors 
showed that ghrelin promotes long term potentiation, a phe-
nomenon that has a positive correlation with spatial memory 
and learning [40]. Animals that received ghrelin injections 
showed in fact enhanced performance in several behavioral 
memory tests that are dependent by hippocampus. Again, 
there is a lack of knowledge concerning the molecular 
mechanisms and transmitters involved. As discussed above, 
ghrelin receptors positively interact with DA and 5-HT re-
ceptors [22, 69] and D1/GHS type 1a co-expression has been 
reported in hippocampus [69]. Since the loss of cognitive 
functions in aging has been supposed to involve a decline in 
DA or 5-HT signaling [8, 15], ghrelin potentiation of these 
neurotransmitters in hippocampus may represent an interest-
ing mechanism to intervene on memory impairment due to 
senescence or Alzheimer disease [8, 40]. On the other hand, 
the still limited number of data available so far leaves open 
the possibility that the effects of ghrelin on mnestic perform-
ances may be primarily related with feeding behavior. The 
model proposed by Diano and coll. [40] implies that circulat-
ing ghrelin is able to reach significant concentrations in the 
hippocampus.Furthermore,Carlini and coll. [20] have shown 
that injections of ghrelin in the hippocampus and DRN in-
creased food intake in a dose-dependent manner. Altogether 
these data suggest that a gut-hippocampus axis may facilitate 
memory retention for the spatial localization of food [99]. 
GHRELIN AND CENTRAL PAIN MECHANISMS 
  The relationship between ghrelin and pain has been the 
subject of very recent investigations, and knowledge in this 
field is still at its infancy. In general terms, currently avail-
able evidence indicates that ghrelin acts as an antinociceptive 
signal at both peripheral and central sites [59, 128, 146]. 
  The early work of Sibilia and coll. [128] provided the 
first convincing evidences that ghrelin may has antinocicep-
tive effects. By using the carrageenan model of acute in-
flammatory pain in rats, these authors showed that ICV in-
jections of the hormone dose-dependently reduce mechanical 
hyperalgesia and paw oedema. A similar effect, albeit at 
slighter levels, was also observed after intraperitoneal, but 
not intraplantar injections. The action of ghrelin was re-
versed by ICV injections of the opioid antagonist naloxone. 
On these bases Sibilia and coll. [128] speculated about the 
possible mechanisms by which ghrelin centrally interacts 
with hypothalamic opioid-containing neurons. In particular, 
they postulated that peripherally administered ghrelin in-
creases agrp synthesis and release [75], which, in turn, en-
hances release of -endorphins from POMC neurons. Alter-
natively, or in addition to, they hypothesized that a ghrelin-
dependent increase of nitric oxide (NO) synthase activity 
[46] may be responsible of the enhanced antinociceptive 
effects of endogenous opioids [62]. In our recent study [146], 
we provided evidence for the existence of central mecha-
nisms of processing of nociceptive signals in spinal cord 
(Fig. 1B). In mouse spinal cord slices, we have shown that 
ghrelin significantly enhances inhibitory (GABAergic/gly-
cinergic) neurotransmission in a subpopulation of deep dor-
sal horn neurons, mainly localized in the medial aspect of 
laminae IV-VI. The effect is specifically due to interaction of 
ghrelin (in its biologically active octanoylated form) with 
GHS-R type 1a, since des-acyl-ghrelin was ineffective. We 
also showed that (D-Lys3)-GHRP-6 (a GHS-R type 1a an-
tagonist) prevents the ghrelin effect. Interestingly, the an-
tagonist reduces per se the frequency of inhibitory post syn-
aptic currents (IPSCs), suggesting that a tonically active re-
ceptor is present in spinal cord. In addition, block of action 
potential-mediated neurotransmission with tetrodotoxin 
strongly reduced the ghrelin effect, indicating that in the dor-
sal horn, unlike the hypothalamus [33], ghrelin receptors do 
not exhibit an axonal distribution. Many deep dorsal horn 
neurons are wide dynamic range (WDR) neurons, and repre-
sent an important site of convergence for nociceptive and 
non-nociceptive stimuli [152]. Ghrelin-responsive neurons 
display the morphology of projection neurons that relay no-
ciceptive information to supraspinal centers and represent the 
main output for lamina II interneurons [152]. It is also likely 
that at least some of them express the neurokinin 1 (NK1) 
receptor, the preferred substance P receptor [112]. It is thus 
conceivable that ghrelin, by increasing the inhibitory input 
onto lamina V projection neurons, leads to a reduction of 
sensory information outflow from spinal cord. To address 
this issue, we studied the effect of the peptide onto the cap-
saicin-induced increase of Fos immunoreactivity in vitro
[146]. Consistently with the idea that ghrelin may exert anti-
nociceptive central effects, capsaicin, a specific activator of 
nociceptive primary afferent fibers that induces Fos expres-
sion in dorsal horn [153], was unable to up-regulate Fos 
within the deep dorsal horn in the presence of ghrelin.  
  Still, considerable work is needed to depict a comprehen-
sive picture of the role of ghrelin in pain central mechanisms. 
Nevertheless, the data reported above suggest that interaction 
with opioid/NPY expressing neurons should be further in-
vestigated to better understand the role of ghrelin as a pain 
modulator.
GHRELIN AS A NEUROPROTECTIVE PEPTIDE 
  Several studies have shown that ghrelin has anti-apop-
totic and protective effects on different types of cells sub-
jected to ischemia/reperfusion injury. The hormone inhibits 
cell apoptosis in cardiomyocytes and endothelial cells [6, 10, 
163], adipocytes [76], cells of the adrenal zona glomerulosa 
[93], osteoblastic MC3T3-E1 cells [77], pancreatic  cells 
[52, 53, 162], intestinal epithelial cells [110], and ovarian 
follicle cells [116]. Moreover, it exhibits protective effects 
against ischemia/reperfusion in gastric mucosa [14], pan-
creas [39], and the isolated rat heart [27, 44]. Recently, it has 
been observed that similar effects are also exerted in CNS, 
where ghrelin inhibits apoptosis during oxygen-glucose dep-
rivation (OGD) [30]. Protection of hypothalamic neurons is 
achieved by inhibition of reactive oxygen species generation, 
stabilization of mitochondrial transmembrane potential, in-
crease of the Bcl-2/Bax ratio, prevention of cytochrome c 
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effects were demonstrated in rat hippocampal neurons after 
ischemia/reperfusion injury, with increase of cell survival 
and reduction of death [89]. In keeping with the observations 
in vivo, primary cortical neurons are protected from apopto-
sis induced by lipopolysaccharide, glutamate, n-methyl-d-
aspartate (NMDA) and H2O2. The anti-apoptotic effect is 
related to up-regulation of Bcl-2 and heat-shock protein 70 
(HSP70), and inhibition of caspases 8, 9, and 3 upon binding 
to GHS-R type 1a [96]. Similarly, apoptosis is blocked in rat 
pheochromocytoma (PC12) cells, where ghrelin reduces 
apoptosis by inducing the expression of HSP70 that, in turn, 
inhibitssignal-regulatingkinase1(ASK1)activity and ASK1-
mediated caspase 3 activation [156].  
  The effect of ghrelin on neuronal survival is not limited 
to neuroprotection, but it also extends to cell proliferation in 
both the embryonic and adult nervous system [73, 122, 159, 
160, 161]. Both the acylated and the des-acylated form of the 
peptide have been shown to promote embryonic spinal cord 
development and neurogenesis [122]. In the adult rat nervous 
system, ghrelin stimulates in vitro and in vivo neurogenesis 
in DMN and NST, after cervical vagotomy [160, 161]. Fi-
nally, the synthetic GHS-R agonist hexarelin and ghrelin 
itself stimulate the incorporation of 
(3)H-thymidine in adult 
rat hippocampal progenitor cells, as an index of increased 
cell proliferation. In addition, hexarelin, but not ghrelin, also 
shows a significant inhibition of apoptosis and necrosis [73]. 
The effects of ghrelin on cell proliferation appear to be 
linked not only to GHS-R type 1a activation, but also to 
other yet uncharacterized peptides [73, 122]. All together, 
these data indicate that ghrelin may also act as a survival 
factor that promotes neurogenesis, preserves tissue integrity 
from ischemic injuries, and inhibits apoptosis. 
GHRELIN PASSAGE ACROSS THE BBB 
  The effects of ghrelin on synaptic transmission, neuronal 
excitability and intracellular calcium levels suggest a trans-
mitter-like behavior. However, as mentioned above, a deter-
minant factor for defining a molecule as neurotransmitter is 
the existence of an endogenous source in neurons or glia. 
The question whether or not a central source of ghrelin does 
indeed exist and plays significant function in neurotransmis-
sion is still under debate. In a previous paragraph, we re-
viewed the most relevant data on expression of the peptide in 
CNS as established after different experimental approaches. 
Unfortunately, these data are often conflicting among each 
other, and a general consensus concerning the anatomical 
distribution of ghrelin-containing neurons and their projec-
tions is still far to be achieved. The reasons for these dis-
crepancies should not only be sought in different sensitivities 
among the experimental procedures employed for localiza-
tion, but, more importantly, in the low level of ghrelin ex-
pression in CNS [81]. In addition, several studies on the cen-
tral effects of ghrelin concerned a number of brain areas 
where local synthesis has not yet convincingly been demon-
strated. This is the case of many extra-hypothalamic areas, 
including hippocampus, midbrain, hindbrain and spinal cord. 
Therefore, in these areas circulating ghrelin is likely to be the 
only endogenous source of the peptide. In this context, the 
possibility that circulating ghrelin may cross the BBB has 
been the obvious subject of several investigations [86, 108]. 
Apart from the SFO and related circumventricular regions 
where the BBB is incomplete [45], it is currently accepted 
that peptide molecules are not capable to cross the BBB. 
However, intravenous ghrelin injections have been reported 
to induce an increased Fos expression also in non-
circumventricular areas [135]. To explain the passage of 
ghrelin across the BBB, the existence of specific transporters 
has been proposed by Banks and coll. [7]. These authors 
studied in mice the blood-to-brain and the brain-to-blood 
passage of intravenously and ICV injected acylated and des-
acylated radioactive-labeled ghrelin peptides. From these 
studies, it appeared that octanoylated mouse ghrelin easily 
crosses the barrier but only in the brain-to-blood direction by 
a saturable carrier system, whereas des-acyl-ghrelin displays 
an opposite behavior due to a non-saturable mechanism. In-
terestingly in mice, human ghrelin, which differs from the 
mouse peptide for two amino acid residues, can be bi-
directionally transported across the BBB by a saturable sys-
tem [7, 40]. Therefore it appears that the transport of acy-
lated and des-acylated ghrelin across the BBB is finely regu-
lated by complex mechanisms, involving both active and 
passive transport. This, in turn, suggests that the bi-
directional transport of ghrelin peptides from brain to extra-
nervous compartments and vice versa is strictly linked to the 
array of biological functions that the peptide potentially ex-
erts both at centre and periphery. However, whereas the 
physiological significance of the passage of the octanoyl 
ghrelin from the hypothalamus to the general circulation may 
be convincingly explained by taking into consideration the 
hormone-like functions of the peptide, retention of des-acyl-
ghrelin in the brain seems less obvious. An interesting possi-
bility is that circulating des-acyl-ghrelin, once entered the 
brain, is sequestered by specific cells that convert the peptide 
into the active octanoylated form. Octanoylation is a unique 
process in animal cells, which requires an appropriate bio-
chemical machinery to be brought to completion. The key 
enzyme in the process has remained elusive, and this has 
rendered particularly difficult the identification of the cells, 
if any, that may be involved in the conversion process. Two 
very recent reports on the characterization of GOAT, the 
ghrelin O-acyl transferase, as a conserved orphan membrane-
bound O-acyl transferase that specifically octanoylates ser-
ine-3 of the ghrelin peptide, open a new avenue in the study 
of the biological effects of the hormone [50, 155].  
  Descending fibers from the hypothalamus are most likely 
the main source of ghrelin in spinal cord, as it appears to be 
the case for certain orexygenic peptides, such as hypocretin 1 
and 2 (or orexin A and B) [35, 143]. This would be in accor-
dance with studies demonstrating the existence of direct de-
scending projections connecting the hypothalamus and the 
spinal cord dorsal horn [25]. However, even though more 
specific studies are needed, our immunocytochemical studies 
do not completely rule out the possibility that the peptide is 
also expressed in DRGs and/or intrinsic neurons of spinal 
cord (unpublished data).  
  In summary, according to our current knowledge, circu-
lating ghrelin is the most important source of the peptide in 
brain and spinal cord. Since circulating ghrelin is mostly 
represented by des-acyl-ghrelin, acylation mechanisms in 
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transcripts for GOAT occur predominantly in stomach and 
pancreas [50], therefore suggesting that CNS is unlikely to 
be a major site of ghrelin acylation. 
CONCLUSIONS AND FURTHER DIRECTIONS 
  Given that ghrelin synthesized in the stomach and re-
leased into the general circulation seems to be the main 
source of the peptide acting on central neurons, one has to 
keep clear in mind that most of the effects of ghrelin in brain 
are likely due to a gut peptide released in the bloodstream 
under fasting conditions [83]. Therefore the central effects of 
the peptide should be placed within a more general frame-
work of adaptive mechanisms facilitating feeding behavior. 
The role of ghrelin in central neurons has encountered in-
creasing interest in recent years, and a coherent scheme of 
ghrelin functions is taking shape. It is clear that the latter 
cannot be confined to the GH-releasing effects or the in-
crease of food intake. The arrays of effects produced by 
ghrelin seem to converge in concert to put the organism in 
the condition of recovering from a negative energetic status. 
Nonetheless, the neuropharmacology of this peptide is still 
poorly understood, and much more work should be done in 
this direction. In particular, it will be of interest to establish 
whether or not des-acyl ghrelin is indeed a neuroactive 
molecule, if receptors subtypes other than GHS-R type 1a 
are responsible for ghrelin and/or des-acyl-ghrelin central 
effects, and how can acylation and des-acylation be regulated 
in the brain.  
  Heterogeneity of ghrelin receptors has already been 
documented outside the CNS [102]. If similar data will be 
obtained also in CNS, they may add new insights in the 
complex pattern of ghrelin functions in the brain. 
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ABBREVIATIONS 
5-HT =  Serotonin 
AgRP  =  Agouti related protein 
AP =  Area  postrema 
ARH =  Arcuate  nucleus 
ASK1  =  Signal-regulating kinase 1 
BBB  =  Blood brain barrier 
CNS =  Central  nervous  system 
CRH =  Corticotropin-releasing  hormone 
DA =  Dopamine 
DMN =  Dorsomedial  nucleus 
DMV  =  Dorsal motor nucleus of the vagus nerve 
DRG  =  Dorsal root ganglion 
DRN  =  Dorsal raphe nucleus 
DVC =  Dorsal  vagal  complex 
EGFP  =  Enhanced green fluorescent protein 
GABA =  -amino butyric acid 
GABAA-R = GABAA  receptor 
GH =  Growth  hormone 
GHRH  =  Growth hormone releasing hormone 
GHS-R  =  Growth hormone secretagogue receptor 
GLY-R =  Glycine  receptor 
GOAT =  Ghrelin  O-acyl  transferase 
HSP70  =  Heat-shock protein 70 
ICV =  Intracerebroventricular 
IP3 =  Inositol-3-phopshate 
Nacc =  Nucleus  accumbens 
NK1 =  Neurokinin  1 
NMDA =  n-methyl-d-aspartate 
NO =  Nitric  oxide 
NPY =  Neuropeptide  Y 
NREMS  =  Non-rapid eye movement sleep 
NTS  =  Nucleus tractus solitarius 
OGD =  Oxygen-glucose  deprivation 
PKA  =  Protein kinase A 
PKC  =  Protein kinase C 
PLC =  Phospholipase  C 
POMC =  Pro-opiomelanocortin 
PVN =  Paraventricular  nucleus 
REMS  =  Rapid eye movement sleep 
SCN =  Suprachiasmatic  nucleus 
SFO =  Subfornical  organ 
TH =  Tyrosine  hydroxylase 
VMN =  Ventromedial  nucleus 
 VTA  =  Ventral tegmental area 
WDR  =  Wide dynamic range 
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